Regeneron Pharmaceuticals (NSDQ:REGN) and its partner, Sanofi (NYSE:SNY), have agreed to lower the cost for its cholesterol drug, Praluent, for Express Scripts (NSDQ:ESRX) in exchange for an exclusive spot on the pharmacy benefit manager’s national formulary.
The agreement, effective July 1, is designed to broaden patient access to the injectable medicine and lower out-of-pocket costs for eligible patients, according to the pharma companies.
Get the full story at our sister site, Drug Delivery Business News.
The post Regeneron, Sanofi strike pricing deal with Express Scripts for cholesterol drug appeared first on MassDevice.